ALSO NOTED: ImaRx prices IPO; Sepracor, Eisai sign deal for Lunesta; and much more...
> GSK has decided not to exercise its option to license Exelixis' non-small cell lung cancer drug XL647 for further development. Release
> ImaRX Therapeutics has priced its IPO at $5 per share. Release
> Chutes & Ladders: Silence Therapeutics has appointed Jeffery Scott Vick as Group CEO. Release
> Sepracor and Eisai have signed a deal development and commercialization of Sepracor's sleep drug Lunesta for the Japanese market. Release
And Finally... According to a Wake Forest University School of Medicine study, a class of drugs (which included Avandia and Actos) used to treat type 2 diabetes may double the risk of heart failure. Report
Be the first to comment Rate it:
More stories about Sepracor Wake Forest University School Of Medicine Avandia Actos GlaxoSmithKline Eisai IPO XL647 ImaRX Therapeutics
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends